文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

幽门螺杆菌治疗未竟议程:耐药、微生态影响与未来方向

The Unfinished Agenda in Helicobacter pylori Treatment: Resistance, Microbiome Effects, and Future Directions.
PubMed 文献 · Gastroenterology · 2026-03-27

本文综述幽门螺杆菌治疗中耐药、最佳方案、生态影响及新兴疗法等未解决问题。全球对大环内酯类、硝基咪唑类和氟喹诺酮类耐药显著削弱传统疗效,药敏指导治疗因基础设施缺乏而受限。优化治疗需循证方案选择、精准策略、抗菌药物管理和公平可及。

要点

  • 全球克拉霉素、甲硝唑和氟喹诺酮类耐药显著削弱传统幽门螺杆菌治疗方案疗效。
  • 药敏指导治疗是成功关键,但因基础设施缺乏在幽门螺杆菌中应用有限。
  • 根除方案可能改变胃和肠道微生态并扩大耐药组,益生菌和N-乙酰半胱氨酸改善有限。

核心结论

  • 优化幽门螺杆菌治疗需循证方案选择、精准指导策略、抗菌药物管理和基本药物公平可及。
  • 分子诊断、抗菌药物研发和实施科学的进步对降低幽门螺杆菌相关疾病和胃癌全球负担至关重要。

研究设计与样本

  • 综述:广泛回顾随机对照试验、荟萃分析、国际共识指南、分子流行病学研究、微生态分析和转化研究。

主要发现

  • 全球对克拉霉素、甲硝唑和氟喹诺酮类耐药显著削弱传统有效抗菌疗法表现。
  • 药敏指导治疗是成功抗菌治疗基石,但因基础设施缺乏在幽门螺杆菌中应用有限。
  • 根除方案可能引起胃和肠道微生态显著改变并扩大抗菌药物耐药组。
  • 益生菌和N-乙酰半胱氨酸对根除率和耐受性改善至多非常有限。
  • 工程噬菌体疗法、抗菌肽、纳米颗粒递送尿素酶抑制剂、生物膜靶向剂和疫苗等新型实验平台显示前景。

临床怎么用

  • 应基于证据选择幽门螺杆菌根除方案,并推行精准指导策略和抗菌药物管理。
  • 需关注根除治疗对微生态和耐药组的影响,并致力于基本药物公平可及。

局限性

  • 实施差距、持续使用次优方案和全球不平等制约现有疗法影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Helicobacter pylori infection is the principal cause of peptic ulcer disease, mucosa-associated lymphoid tissue lymphoma, and noncardia gastric cancer. The major advances in diagnostics and treatment and eradication success are threatened by rising antimicrobial resistance and concerns about disruption of the normal microbiome. This review summarizes current unresolved issues in H pylori treatment, with a focus on resistance, optimal regimens, ecological impact, and emerging therapies. METHODS: Extensive review of randomized controlled trials, meta-analyses, international consensus guidelines, molecular epidemiology studies, microbiome analyses, and translational research related to H pylori eradication, resistance, microbiome effects, and novel therapies. RESULTS: Global resistance to clarithromycin, metronidazole, and fluoroquinolones significantly undermines the performance of traditionally effective antimicrobial therapies. The corner stone of successful antimicrobial therapy is susceptibility-guided therapy but remains of limited use with H pylori because of lack of infrastructure. Eradication regimens potentially induce substantial alterations in gut and gastric microbiota and expand the antimicrobial resistome. Probiotics and N-acetylcysteine offer at best very modest improvements in eradication and tolerability. Novel and still experimental platforms, including engineered phage therapy, antimicrobial peptides, nanoparticle-delivered urease inhibitors, biofilm-targeting agents, and vaccines show promise. Implementation gaps, persistent use of suboptimal regimens, and global inequities constrain the impact of available therapies. CONCLUSIONS: Optimizing H pylori treatment requires evidence-based regimen selection, precision-guided strategies, antimicrobial stewardship, and equitable access to essential medications. Advances in molecular diagnostics, antimicrobial development, and implementation science are all critical to reducing the global burden of H pylori-associated disease and gastric cancer.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Rokkas T, Graham DY. The Unfinished Agenda in Helicobacter pylori Treatment: Resistance, Microbiome Effects, and Future Directions. Gastroenterology. 2026. PMID: 41905430. doi:10.1053/j.gastro.2026.02.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。